Fermenta Biotech reports surge in H1FY26 revenue and profit

Fermenta Biotech Limited (FBL) has reported a robust financial performance for H1FY26, with consolidated revenues reaching INR 280.7 crore, marking a 57% year-over-year increase. Net profit soared by 664% year-over-year to INR 39.6 crore, while EBITDA grew by 173% to INR 69.1 crore. For Q2FY26, consolidated revenues were INR 135.7 crore, up 39% year-over-year.

The company's human nutrition segment volumes expanded by 74% over H1FY25, contributing significantly to overall growth. Vitamin D3 – Human Nutrition revenues increased by 80% to INR 158.8 crore. Additionally, the German toll manufacturing subsidiary's H1FY26 revenue surged by 194% to INR 34.3 crore, with EBITDA up 103% to INR 7.7 crore.

Fermenta Biotech also announced that the Indian Patent Office granted a patent in September 2025 for its plant-based Vitamin D3 manufacturing process. Furthermore, the board approved the transfer of the 'Environment Division' to a wholly owned subsidiary, Fermenta Environment Solutions Private Limited, for INR 19 crore, effective October 1, 2025.